-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $746.958M Est

Benzinga·08/04/2026 20:13:14
语音播报
Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $746.958 million estimate.